Search Results
Mar 23, 2026, 08:00 ET Cambrex treibt seine Expansion in den USA und Europa voran
23. März 2026 /PRNewswire/ -- Cambrex, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO), gab heute den Abschluss der ersten technischen Studien für seine neue Großanlage zur Herstellung pharmazeutischer Wirkstoffe (API) in Charles City,
More news about: Cambrex
Mar 23, 2026, 08:00 ET Cambrex Advances US and European Expansions
March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in
More news about: Cambrex
Mar 23, 2026, 08:00 ET Cambrex avança nas expansões nos EUA e na Europa
23 de março de 2026 /PRNewswire/ -- Cambrex, organização líder global de desenvolvimento e fabricação por contrato (CDMO), anunciou hoje a conclusão dos estudos iniciais de engenharia para sua nova planta de fabricação de ingredientes farmacêuticos ativos
More news about: Cambrex
Mar 23, 2026, 08:00 ET Cambrex poursuit son expansion aux États-Unis et en Europe
23 mars 2026 /PRNewswire/ -- Cambrex, une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan, a annoncé aujourd'hui l'achèvement des études techniques initiales pour sa nouvelle usine de fabrication de principes actifs à grande
More news about: Cambrex
Mar 23, 2026, 08:00 ET Cambrex impulsa su expansión en Estados Unidos y Europa
23 de marzo de 2026 /PRNewswire/ -- Cambrex, una organización líder mundial en desarrollo y fabricación por contrato (CDMO), anunció hoy la finalización de los estudios de ingeniería iniciales para su nueva planta de fabricación de principios activos farmacéuticos (API) a
More news about: Cambrex
Mar 23, 2026, 08:00 ET 캠브렉스, 미국 및 유럽 확장 추진
규모의 확장 프로젝트가 진행 중이다. 이 프로젝트를 통해 신규 분석 개발 및 공정 연구개발(R&D) 역량이 추가되고, 여러 생산 공장에 대한 업그레이드도 이뤄질 예정이다. 밀라노 R&D 확장은 2027년 하반기에 완료될 것으로 예상되며, 향후 성장과 CDMO 서비스 수요 증가에 대응하기 위해 추가 부지도 확보한 상태다.클라우디오 루솔로(Claudio Russolo) 최고운영책임자(COO)는 "이탈리아 밀라노 공장은 제약 개발과 제조를 지원해 온 훌륭한 유산을 보유하고 있으며, 올해로 운영 80주년을 맞았다.
More news about: Cambrex
Mar 23, 2026, 08:00 ET OFD Life Sciences Awarded Patent for Breakthrough Innovation in ODT Manufacturing
Oregon Freeze Dry, one of the largest and most technologically advanced freeze-dryers in North America. OFD Life Sciences is a specialized CDMO focused on providing solutions to biopharma, consumer health, and animal health companies through its deep expertise in lyophilization. Featuring LyoLock™
More news about: OFD Life Sciences
Mar 23, 2026, 06:04 ET WuXi AppTec Beat Full-Year Guidance and Achieved Record Performance in 2025
partnerships that underpin the sustainable growth of our CRDMO business.Small molecule D&M service remains strong.i. The small molecule CDMO pipeline continued to expand. In 2025, small molecule D&M revenue rose 11.4% YoY to RMB 19.92 billion. We added 839 new molecules to the small molecule
More news about: WuXi AppTec
Mar 19, 2026, 07:50 ET Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
Company's CDMO subsidiary.During the conference, the team will meet with pharmaceutical and biotechnology companies, investors, and prospective clients to advance both Scinai's innovative R&D pipeline and its integrated CDMO offering.Expanding a Differentiated Integrated CDMO Platform
More news about: Scinai Immunotherapeutics Ltd.
Mar 18, 2026, 10:00 ET Cenevo's Labguru Drives Digital Lab Transformation for Pace® Life Sciences
solution to centralize documentation processes at Pace® Life Sciences, a U.S.-based contract development and manufacturing organization (CDMO) and full-service good manufacturing practice (GMP) analytical laboratory service provider.
More news about: Cenevo
Mar 18, 2026, 10:00 ET New England Biolabs® releases EnClose™ Cell-free dbDNA™ Synthesis Kit in collaboration with Touchlight to accelerate DNA and RNA therapeutic development
www.neb.com.About TouchlightTouchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed
More news about: New England Biolabs, Inc.
Mar 17, 2026, 10:08 ET Cellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first
More news about: Cellipont Bioservices
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy und Viralgen kündigen strategische Zusammenarbeit zur Herstellung von TfR1 CapX an, einem Kapsid der nächsten Generation für Gentherapien zur Behandlung von Erkrankungen des zentralen Nervensystems
Generation für die Verabreichung von genetischen Medikamenten entwickelt, und Viralgen, ein führendes Auftragsentwicklungs- und -herstellungsunternehmen (CDMO), das sich auf Gentherapien in Verbindung mit rekombinanten Adeno-assoziierten Viren (rAAV) spezialisiert hat, gaben heute eine strategische Produktionskooperation
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy y Viralgen anuncian una colaboración estratégica para la fabricación de TfR1 CapX
de próxima generación para la administración de medicamentos genéticos, y Viralgen, una organización líder de desarrollo y fabricación por contrato (CDMO) especializada en terapias génicas con virus adenoasociados recombinantes (rAAV), anunciaron hoy una colaboración estratégica de fabricación para respaldar
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy et Viralgen annoncent une collaboration stratégique pour la fabrication de TfR1 CapX, une capside de nouvelle génération pour les thérapies géniques destinées à traiter les maladies du système nerveux central.
AAV de nouvelle génération pour délivrer des médicaments génétiques, et Viralgen, une organisation de développement et de fabrication sous contrat (CDMO) de premier plan spécialisée dans les thérapies géniques par virus adéno-associés recombinants (rAAV), ont annoncé aujourd'hui une collaboration stratégique
More news about: Viralgen
Mar 17, 2026, 08:36 ET Lo stabilimento di Grangemouth, nel Regno Unito, di Piramal Pharma Solutions consegna con successo il 1500° lotto di ADC
oltre vent'anni, Piramal Pharma Solutions è leader mondiale nello sviluppo e nella produzione di ADC. In qualità di prima CDMO specializzata in ADC, approvata dalla FDA e prima CDMO a produrre un ADC in ambito commerciale, Piramal dimostra una competenza senza pari in questo settore.Piramal sfrutta
More news about: Piramal Pharma Solutions
Mar 17, 2026, 08:33 ET Abzena Recognized as a Market-Leading Antibody-Drug Conjugate CDMO in Frost & Sullivan Radar Report
end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the Frost Radar™ Report for Antibody-Drug Conjugate Contract Development and Manufacturing Organizations. Frost & Sullivan recognized Abzena as a technology-forward CDMO, citing its proprietary
More news about: Abzena
Mar 16, 2026, 22:07 ET Werk von Piramal Pharma Solutions im schottischen Grangemouth liefert erfolgreich die 1.500ste ADC-Charge aus
Jahrzehnten ist Piramal Pharma Solutions weltweit führend in der Entwicklung und Herstellung von ADCs. Als erstes von der FDA zugelassenes CDMO für ADCs und als erstes CDMO, das ein ADC kommerziell herstellt, beweist Piramal eine einzigartige Kompetenz in diesem Segment.Piramal nutzt dieses Fachwissen,
More news about: Piramal Pharma Solutions
Mar 16, 2026, 22:05 ET L'usine de Piramal Pharma Solutions à Grangemouth, au Royaume-Uni, livre avec succès le 1 500ᵉ lot d'ADC
plus de 20 ans, Piramal Pharma Solutions est un leader mondial dans le développement et la fabrication d'ADC. En tant que premier CDMO d'ADC approuvé par la FDA et premier CDMO à fabriquer un ADC à des fins commerciales, Piramal fait preuve d'une compétence inégalée dans ce segment.Piramal s'appuie
More news about: Piramal Pharma Solutions
Mar 16, 2026, 16:05 ET Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
and from PinCell S.r.l.Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.Company website:
More news about: Scinai Immunotherapeutics Ltd.
Mar 16, 2026, 09:29 ET La planta de Piramal Pharma Solutions en Grangemouth, Reino Unido, entrega con éxito el lote 1.500 de ADC
Pharma Solutions ha sido líder mundial en el desarrollo y la fabricación de conjugados anticuerpo-fármaco (ADC). Como la primera CDMO de ADC aprobada por la FDA y la primera CDMO en fabricar comercialmente un ADC, Piramal demuestra una competencia inigualable en este sector. Piramal aprovecha esta
More news about: Piramal Pharma Solutions
Mar 16, 2026, 06:26 ET GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
AI-driven drug development, and multi-antibody drug development, fueling growth in gene-to-protein businesses, (iv) harnessing rebound in biologics CDMO demand and capitalizing on recovering market conditions, (v) continuous market expansion supported by launch of innovative industrial enzyme products.Gross
More news about: GenScript Biotech Corporation
Mar 16, 2026, 06:10 ET GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
AI-driven drug development, and multi-antibody drug development, fueling growth in gene-to-protein businesses, (iv) harnessing rebound in biologics CDMO demand and capitalizing on recovering market conditions, (v) continuous market expansion supported by launch of innovative industrial enzyme products.Gross
More news about: GenScript Biotech Corporation